The Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents have been updated!
Revisions are largely based on findings from two large, randomized controlled trials that addressed the optimal time to initiate ART -- START and TEMPRANO.
Please send any comments to firstname.lastname@example.org.
(Last updated: May 1, 2014; last reviewed: April 8, 2015)
|Generic Name (Abbreviation)/ Trade Name||Formulation||
|150 and 300 mg tablets||150 mg BID when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except TPV/r)
300 mg BID when given with NRTIs, T20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers
600 mg BID when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)
Take without regard to meals.
|14-18 hours||CYP3A4 substrate||
a (For dosage adjustment in hepatic insufficiency, see Appendix, Table 7.)
b Also see Table 14.
Key to Abbreviations: BID = twice daily; CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; T20 = enfuvirtide; TPV/r = tipranavir/ritonavir